Alembic Pharma receives US FDA approval for fulvestrant injection

Alembic Pharma receives US FDA approval for fulvestrant injection

By, Admin 27 December 2022

Drug major Alembic Pharmaceuticals said that it has received a final approval from the US Food & Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), fulvestrant injection 250 mg/5 ml (50 mg/ml) per single-dose prefilled syringe. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Faslodex injection, 250 mg/5 ml (50 mg/m) of AstraZeneca Pharmaceuticals LP. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of breast cancer. According to IQVIA, fulvestrant injection has an estimated market size of USD 71 million for twelve months ending September 2022. The pharmaceutical company said that it has received a cumulative total of 179 ANDA approvals (156 final approvals and 23 tentative approvals) from US FDA. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!